You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Self-Sealing Therapy Ostomy Pouch

    SBC: Korosensor.Com, Inc.            Topic: 300

    DESCRIPTION provided by applicant Eden Medical proposes to develop a Self Sealing Therapy Ostomy Pouch S TOP to stop leakage that leads to skin breakdown and trauma for ostomy care patients The S TOP will detect leakage inform the patient and prevent leakage occurrence providing better patient comfort and well being and eliminating the cycle of misery due to an ineffective seal and skin br ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention

    SBC: HEALTHCARE INTERACTIVE, INC.            Topic: NIA

    DESCRIPTION provided by applicant As the US population ages Alzheimerandapos s disease and related disorders ADRD will present an emotional and financial burden to an increasing number of families and the U S healthcare system More than of the care for persons with ADRD is provided by family members at home who need ongoing support to manage the daunting physical and psychological demands of care ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: TECHSHOT, INC.            Topic: 200

    DESCRIPTION provided by applicant Techshot Inc has successfully completed SBIR Phase I and Phase II research demonstrating that magnetically labeled porcine islets of Langerhans can be isolated from contaminating exocrine tissue by flow sorting using a quadrupole magnetic separator andquot Quadrasepandquot designed for that purpose Magnetically sorted islets are superior in morphology and ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Computational tools to analyze SNP data from patients with mental illness

    SBC: PARTEK, INC.            Topic: 101

    DESCRIPTION provided by applicant The broad long term objective of the proposed research is to develop and market a commercial software product that can be used to facilitate the analysis of genetic changes in order to elucidate chromosomal abnormalities that underlie diseases such as autism spectrum disorder bipolar disorder and schizophrenia Recent technological advances allow samples of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government